Literature DB >> 30190908

Are PD-1 antibodies safe for use in metastatic uveal melanoma?

Katy K Tsai1, Alain P Algazi1.   

Abstract

Entities:  

Keywords:  PD-1; PD-L1; atezolizumab; immunotherapy; nivolumab; pembrolizumab; safety; toxicity; uveal melanoma

Year:  2017        PMID： 30190908      PMCID： PMC6094660          DOI： 10.2217/mmt-2017-0007

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  22 in total

1.  Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

Authors:  Riccardo Danielli; Ruggero Ridolfi; Vanna Chiarion-Sileni; Paola Queirolo; Alessandro Testori; Ruth Plummer; Monica Boitano; Luana Calabrò; Costanza De Rossi; Anna Maria Di Giacomo; Pier Francesco Ferrucci; Laura Ridolfi; Maresa Altomonte; Clelia Miracco; Angelo Balestrazzi; Michele Maio
Journal:  Cancer Immunol Immunother       Date:  2011-08-11       Impact factor: 6.968

2.  Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant.

Authors:  Noah Frydenlund; Dominick Leone; Shi Yang; Mai P Hoang; April Deng; Marier Hernandez-Perez; Rajendra Singh; Asok Biswas; Ron Yaar; Meera Mahalingam
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

5.  Targeting oncogenic drivers and the immune system in melanoma.

Authors:  Grant A McArthur; Antoni Ribas
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

6.  Very long-term prognosis of patients with malignant uveal melanoma.

Authors:  Emma Kujala; Teemu Mäkitie; Tero Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-11       Impact factor: 4.799

7.  Incidence of uveal melanoma in the United States: 1973-1997.

Authors:  Arun D Singh; Allan Topham
Journal:  Ophthalmology       Date:  2003-05       Impact factor: 12.079

8.  Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

Authors:  Jason J Luke; Margaret K Callahan; Michael A Postow; Emanuela Romano; Nikhil Ramaiya; Mark Bluth; Anita Giobbie-Hurder; Donald P Lawrence; Nageatte Ibrahim; Patrick A Ott; Keith T Flaherty; Ryan J Sullivan; James J Harding; Sandra D'Angelo; Mark Dickson; Gary K Schwartz; Paul B Chapman; Jedd D Wolchok; F Stephen Hodi; Richard D Carvajal
Journal:  Cancer       Date:  2013-08-02       Impact factor: 6.860

9.  The use of pembrolizumab for the treatment of metastatic uveal melanoma.

Authors:  Lisa A Kottschade; Robert R McWilliams; Svetomir N Markovic; Matthew S Block; Jose Villasboas Bisneto; Anthony Q Pham; Brandt L Esplin; Roxana S Dronca
Journal:  Melanoma Res       Date:  2016-06       Impact factor: 3.599

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.